Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
https://www.reddit.com/r/RVVTF/comments/121xidv/request_for_presentation/
If you care to simply put aside at what's being requested, BMT does have some good thoughts on how to proceed forward.
Provide links. I want to hear the crying first hand
Everyone should check out reddit or Facebook revive pages and look at the recent post about getting 5% of the shareholders to ask MF Q & A to clarify our path forward. The reddit it by nick Nintendo and BMT. The Facebook Nick. They are trying to have everyone sign up by this upcoming Thursday.
What fake news? Only fake news I recall is MF telling us he’s moving to NJ back in Sept 2022
Heard a rumor he’s still playing golf in the Bahamas. Dude is screwing shareholder ever day.
Don’t believe put me on ignore.
Well stated ragstorum.
Reliefs OS is huge......over 4.4 BILLION to be clear.
The joker has been throwing this dried crap at the wall trying to make it stick since 2020.
Its as dumb today as it was back then but yet again here it is.
Revive doing an rs now, despite recently raising $4.3M, makes zero sense and even if its done to raise the pps for an uplist, that also is nonsensical since the OS would be reduced to about 2M shares.
OT: On a side note, snpw's current depressed pps after the run to 34s was primarily the result of a court in RI siding with the plaintiffs that opposed the construction of the Medrecycler plant.
The $17M funding for the project was already secured and had the plant been approved the pps would have indeed hit $1+.
Pmpng absolutely did occur but the facts re the project were facts, not just the selective ones ye quoted.
It seems we all trade and have an agenda here.
No problem with that - we make our case to influence others
because it suits our interest. That's trading.
My agenda is to push the science and profit from validated research.
I’ve heard that same argument many times. It just doesn’t hold water over the long term.
Reading recent fake-news-rag lines about RVVTF and the CEO reminds me of the story about the guy that burned down his house using gasoline and a match, and then he blamed the house for the fire, blamed the house not being fireproof LMAO....
LMAO, that is BS, only a fool would R/S a stock with this low of an OS. There are stocks out there on OTC with 40 Bil shares.
1) they will not go to Nasdaq until they succeed with the Bucci/FDA deal.. When that happens the $$$ share price will mean no R?S needed.
2) They just raised 4.3 mil in cash at 0.10 Us dollars/share. Only a fool would do a R/S right now in this market.
Indeed:
"True character is shown in times of adversity.
The ultimate measure of a man is not where he stands in moments of comfort and convenience, but where he stands at times of challenge and controversy.
P.S. RVVTF and Bucillamine. You stood me up, but that's OK. I still think you're hot. "
$RVVTF and the CEO MF are standing tall
Speaking of RVVTF standing us up and being OK because she is hot, I agree
IMO, the folks that invested 4.3 Mil dollars at .10/share US dollars/share for restricted, no liquidity shares, are quietly laughing LTAO, sitting and buying these insurance priced gift shares from the fools of the market place.... selling down here. Would not be surprised if MM's are shorting and wash trading shares to try and pick off weak hands, that is how they make money after all...
"Never seen an offering above current market get concluded and then lose 75% just weeks later "
Not surprised, but because I have a lot more experience in these stocks,.... I have, in fact I helped one raise cash at .21/share in 2014 when the lows had hit .04 and recently, seen it in another Biotech, Athx, that fell from the $1 to $3 range it traded at for 10 years (to .12/share) while burning up cash on multi stem research for decade, 100s of millions....
And it raised 12 Million dollars just after only to get R/S days later and lost another 80% of the share price it raised the $12 Million dollars at and the fell another 70%, only to rally 200% since then, and managed to stay on Nasdaq.
Institutional firm put in the 12 Million dollars, took a huge paper loss, then made a second deal for more shares and warrants..
The last the last 14 months has been brutal to Bio-tech drug start ups, pre revenue, pre-profits.
That is obvous and well know to ones who have been in the market for decades.
I was trading the week the DOW dropped 40% in 3 days in 1987. I made a pile of money buying the knife on day three.....
The said part is I seem to be the only one that sees what is really going with RVVTF.
It has nothing to do with the CEO nurse maiding or not nurse maiding retail share holders.
Yes. That is correct. But I’ve seen plenty of penny stock do it at these o/s levels as well however the lower o/s here does reduce the risk imo!! I read somewhere that MF did do one before in a previous job.
But, compared to Revive (RVVTF) unless i'm wrong RLFTF's outstanding shares are in the billions?
RLFTF just announced they will be doing one. I'll have to lick my wounds on that one when that happens. Dilution always follows. They, like RVVTF, touted a grand covid therapy. That's what these tiny penny stocks do when they need more money to pay their salaries and bonuses. Due to the need to raise funds, the time horizon for making a decent profit with penny stocks is typically very narrow, A few years a ago a wise penny stock investor once posted ---- it's not wise to hold penny stocks that are below a dime with a high o/s for very long, because bad things eventually tend to happen. He is so right!
That will be absolute murder
gov.. High probability that r/s will be next in line. O/S > 320M. JMHO
Did you buy the offering at .15? Nothing reeks scam like that one
Never seen an offering above current market get concluded and then lose 75% just weeks later
True character is shown in times of adversity.
The ultimate measure of a man is not where he stands in moments of comfort and convenience, but where he stands at times of challenge and controversy.
P.S. RVVTF and Bucillamine. You stood me up, but that's OK. I still think you're hot.
Ecomike, you know I have valued many of your posts historically however, I disagree with your response here. That would represent an emotionally-backed stance and reeking of retaliation not to mention borderline vindictive by CEO MF.
CEO Michael Frank, like all good 'leaders' tend to do, should recognize investor sentiment after Monday's dire update and subsequent PPS plunge, and exercise some emotional intelligence at this point by addressing shareholders in a somewhat personalized manner - many of my CEO's do this and it proves effective at the best of times. MF and this whole FDA process has had us all sweating for going on 3 years now and the build-up has resulted in this current toilet-PPS.
Most of us Longs are looking at 80+% paper losses at present. MF needs to give us a status update / strategy to believe in. We merit that to say the least.
His silence stance appears both potentially dodgy and guilty in my opinion (mere speculation based on his action and I hope I am proved otherwise soon). Him communicating with us might effectively eliminate this sentiment, reduce the dumping and increase / encourage new investment.
If MF was confident about Bucillamine and Revive's future, he would and absolutely ought to be vocal about it.
I am an optimist by nature however, the crooked OTCM has screwed me left, right and center these past 18 months - 'hope' is no longer a strategy as an investor and based on his radio silence, hope is all MF is leaving us with currently.
Retail's spinless whining and blaming the $RVVTF CEO for retail's own weak hands, and the US FED's massacre of the banks and stocks and stock markets, just to fix the FED's mistakes is just that, spinless...
Facts matter, https://www.ahip.org/how-big-pharma-makes-big-profits-on-orphan-drugs
and
BS should be ignored.
88 % of orphan drugs cost more than $10,000 per year per patient. 7 /10 best-selling drugs in 2017 had orphan indications. 80 %+ is the gross profit margin for the rare disease industry.
The pharmaceutical industry average gross profit margin is 16%. Orphan drugs are being approved - and entering the market - at higher rates than ever before.
https://www.the-scientist.com/features/how-orphan-drugs-became-a-highly-profitable-industry-64278
"Between 2000 and 2012, orphan drug companies had a 9.6 percent higher return on investment than non-orphan drug producers.6 "I think the traditional model of a blockbuster drug, [such as] statin, where you've got low cost and [you're] prescribing to hundreds of millions of people, has changed," Hughes says."
https://justcareusa.org/orphan-drug-act-delivers-big-profits-to-drug-companies/
"Express Scripts, a drug benefits manager, told Kaiser Health News that it currently has four orphan drugs on its formulary with $70,000 price tags for a 30-day supply-$840,000 annually. Twenty-nine more orphan drugs have price tags of $28,000 for a 30-day supply-$336,000 annually"
https://www.novartis.com/news/novartis-receives-fda-orphan-drug-designation-nis793-pancreatic-cancer
Novartis receives FDA Orphan Drug Designation for NIS793 in pancreatic ...
Jul 27, 2021Novartis receives FDA Orphan Drug Designation for NIS793 in pancreatic cancer Jul 27, 2021 Novartis today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for NIS793 in combination with standard of care chemotherapy for the treatment of pancreatic cancer.
https://www.fiercepharma.com/pharma/celgene-bms-novartis-expected-to-top-2022-orphan-drug-sales-total-pool-worth-209b-report
More than 30 years ago, to foster drug innovation for rare diseases, Congress passed the Orphan Drug Act. The law helps drug companies make big profits on drugs that treat rare diseases–orphan drugs–which affect fewer than 200,000 people. As it turns out, the Orphan Drug Act also enables drug companies to drive up drug prices, along with profits, whenever they can show that their mass-market drugs treat rare diseases.
One in ten Americans has a rare disease, and there are more than 7,000 rare diseases. But, until 1983, drug companies had no profit motive to develop drugs to treat these diseases. The Orphan Drug Act gives drug companies substantial tax credits and seven more years of monopoly pricing power for drugs classified as orphan drugs after their patents expire. In 2016 alone, according to a Kaiser Health News Investigation, the drug companies received $1.76 billion in tax credits for their development and almost $50 billion in tax credits are projected between 2016 and 2025.
While the law has led to drug innovations to treat rare diseases, it also has led to a number of mass-market drugs being reclassified as orphan drugs, with all accompanying financial benefits. The Orphan Drug Act legally entitles them to these benefits as many times as they can show the FDA that a drug treats a rare disease. For example, Gleevec, a cancer treatment, has nine orphan drug approvals, even though it was originally intended to treat far more than 200,000 people. Novartis, its manufacturer, has successfully sliced up the population into small special needs groups and found ways to show that Gleevec meets their unmet needs.
To date, pharmaceutical companies have “developed” 450 new orphan drugs with billions of taxpayer dollars. Of those drugs, the FDA has classified more than 70 mass-market drugs, including seven of the top ten best-selling drugs, as orphan drugs. Crestor, which helps lower cholesterol, Abilify, which treats schizophrenia and depression, and Humira, which treats rheumatoid arthritis, are all now classified as orphan drugs. It’s no wonder that orphan drug sales are expected to account for more than 20 percent of all brand-name drug sales.
The prices for these orphan drugs are astronomical. The Kaiser Health News investigation reveals that in 2014, the yearly cost of an orphan drug was $111,820 instead of $23,331 for other drugs. Express Scripts, a drug benefits manager, told Kaiser Health News that it currently has four orphan drugs on its formulary with $70,000 price tags for a 30-day supply–$840,000 annually. Twenty-nine more orphan drugs have price tags of $28,000 for a 30-day supply–$336,000 annually. And sales of orphan drugs are growing rapidly, at a projected rate of 12 percent a year.
What fake news?
Agree Mike this one has sub penny written all over it. I guess if you can’t wait for 10-20yrs you should sell now?
Of course it can. I am in one stock I saved personally, that looked dead for 4 years, with a 1.5 Mil dollar hole in its balance sheet.
It now owns 74.85 acres of land, the buildings, the plant/factory, is fully funded, and can change the way the world feeds cattle. It was .0005 at the bottom. I am holding for $20/share.
I bought Tgtx in 2009 at .001, it was road kill, in 2021 it hit over $50/share.
IMO, the current $RVVTF share price has nothing to do with Covid19 trial and status.
Snpw in 2020 hit .0005, and rallied it, with my own DD to .345 in 8 trading days. Perfect timing, with the right DD, on an OTC stock with billion shares float. It still 2 years later trades in 1 cents range the last 6-9 months. With a billion share float on no revenue.
There is MM/shorts BS games going on right now with RVVTF, and obvious fake news attempts to drive the share price down. And it has nothing to do RVVTF drug trials and its future.
Been in stocks for 45 years and OTC for 15 years...So I know what to look for, and I am one of the few with real science and engineering background, patents, grants and so on, that public company experience and stock market investing experience...
MF listed that as option 4
Of course if your down 5figures or worse it probably doesn’t make sense to sell and hope for some sort of partnership
The fact that it’s option 4 and some how MF now concludes this is the 4th option doesn’t entice me to buy. I made a trade on the dip and short lived rip
I don’t think a partnership will happen anytime soon but if I thought there was a real chance I will consider when this gets to .02 or lower
My eyes see that on the horizon before any big move north.
My opinion only Mike (Frank)
BS, Novartis gets, charges 1 Million dollars for its new drug, for each dose.
Facts Matter.
Keep up the good work Ecomike.
I continue to be a buyer also.
Keep up the good work Ecomike.
I continue to be a buyer also.
lol nice one
Ric is the only reason we aren’t at .02. He keeps collecting garbage rvv. Lossless
You’re using a 3 year old post from Pumper Mike as your basis?! LOL
He’s threatening people that email him over on the reddit boards with his lawyer. Laughable CEO behavior
MF he not stupidity or ignorance he 's full of craps.
Noticing a calculated trend by a bunch of FR??DS trying to CONvince everyone using misinterpretation, misquotations and blatantly false statements, that the only option is to sell out on the dirt cheap to BP........#scammers!!!
LIE #1 : You said it yourself. The only options here are to sell off to BP
I did??? I made no such comment. All I stated was that the handling of the ep process by RVV was inept but the fact remains that RVV has ZERO control over what the FDA requests so basically they were at the mercy of the FDA. One can only wonder IF the requests were valid, OR CONtrived to force RVV to capitulate, ie constantly raising the bar to ensure failure!?!?
LIE #2 : made a submission that was flawed, inadequate and thus doomed to fail? You mean like the pcr request which was explicitly outlined in fda documents as not an adequate endpoint?
Again, reread what I posted.....the pcr result ep usage was made prior to the type c consultations and therefore had nothing to do with RVVs decision to end the ep change quest. I clearly stated that they did not go forward because that would mean the trial data would need to be unblinded and since the original trial did not contain the data the fda requested it would have obviously failed solely on that basis. The false equivalence is purely asinine to put it mildly and the fact that being asked by the fda to REVISE a submission is falsely being referred to as FAILED, me thinks some should purchase a Dictionary. I am fully aware why its all being pushed in this hyper negative light so have at it..........
LIE #3 : Only option 4 re: strategic partnership is viable in terms of stockholder value and clearly no one believes that talks are happening cause the pps continues its downward spiral
What the market does is many times irrelevant to the actual value of a stock. As people panic seeing the fall in the pps they sell thus further depressing the pps even lower. None of this changes the fact that Buccy may still have great value as the science clearly shows. No one has control over what MMs, Hedgies or Board Agitators post in their attemmpts to create a narrative that RVV is worthless.
The screeching at this point is asphyxiating and the fact that its only intensifying speaks volumes, but by all means do CONtinue as I will be gobbling up as much as I can afford at this time!!! lololsss
Post from 2020 seems applicable now so w'ell see...................
Wednesday, December 16, 2020 6:50:03 PM
Post# 19945 of 35264
Before BIG NEWS breaks I expect a coordinated ""attack"" similar to or worse than today's drop off to 45.
When that happens it will involve a combination of Shorting, Misinformation via Media/Msg Board(s) and a coordinated sell-off by a "Team" of holders.
Today was just a test run IMO....witnessed it happen before.
WHEN GREED IS INVOLVED...EXPECT ANYTHING!!!!
@Eco.........no I dont, sorry.
He has been spineless for a year. He thinks he is this tough guy who is so great at his job but when it comes down to it he has done nothing for 3 years and when someone points that out he pouts and hides from shareholders. He doesn’t have the balls to face questions because all his lies would unravel.
CEO Michael Frank must address shareholders (at this alarming point). To not do so would be utterly spineless. And costly to all.
What kind of time table do you think this little company has with their limited resources to do all these things that you even admit takes BP years to complete Mike?
You want a 50-1 reverse stock split? How else do you imagine they avoid cash burn on the ~$3 million they have and the declare bankruptcy for BP to pick up for pennys?
You laid out next steps that could take years. A large long Covid study? 2 years? 3? It took that long for this study and then was when there were millions of subjects as possibilities
LOL No criticizing of an executive and company that has driven the stock price and shareholder wealth to all time lows.
Just shut up and do as told comrades.
And this perspective is why someone like MF who is out over his heels deserves criticism for not seeking out assistance. They brought in Biomedical Trader for consultation and then IGNORED his advice.
The orphan drug indication is a niche. They aren’t doing tens of thousands of these procedures a year.
Minimal revenues
If Revive is continuing the trial maybe they can add symptoms check this time to the protocol and give the FDA what they want for the next 700 patients. Nobody is going to the hospital whether they gulp down a placebo or Buccy.
ps. I hope none of us longs die before we are unblinded. That would suck.
The ceo was also not ready to launch the trial once the FDA gave the green light....even though he had many months to prepare in advance. Months got lost in him setting up and launching trial after the FDA gave the go ahead. That was the big red warning light for me! I knew then that his priorities were backwards and all about shrooms.
Eco, this is all fine and good but can Revive stay in business for the long haul??
Neither.
MF spending investor money in all the wrong places
Imagine if you participated in the offering at .15 just 10-12 weeks ago.
I’d call that a rug pull
Followers
|
339
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
36630
|
Created
|
02/23/17
|
Type
|
Free
|
Moderators Classic Warrior |
Scientific Rationale of Bucillamine
Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.1 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to restore antioxidant and to reduce the activity of cellular glutathione 2,3,4,5. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via restoration of glutathione activity and other anti-inflammatory activity, to lessen the negative consequences of SARS-CoV2 infection in the lungs.
| Psilocin Pharma Corp. has developed production solutions for the active compound Psilocybin. Our process encompassed with our intellectual property cover methods of production of Psilocybin based formulations. Psilocin Pharma Corp’s range of products have been engineered to work synergistically with the body's own natural pathways of absorption while offering a contemporary approach to consumption. Psilocin Pharma also has strong relationships with specific lab partners in certain areas like Brazil, where these formulations are legally approved and plan to sell products in these jurisdictions. | |
| |
Mental Health (Depression, PTSD & Anxiety)
|
Supplements for Brain Health & Cognitive Enhancement
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |